Corvus Pharmaceuticals

CRVS · Nasdaq · United States

Share price · CRVS

$10.19-4.64 (-31.29%) 3M

close as of 2026-11-18 · 24h delayed · vol 988K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CRVS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+8.3%
  2. 22 Oct 2026+6.0%
  3. 24 Sep 2026-5.9%
  4. 22 Sep 2026+8.2%
  5. 16 Sep 2026-5.6%
  6. 11 Aug 2026+7.2%
  7. 14 May 2026-13.8%
  8. 23 Apr 2026-10.3%
  9. 21 Apr 2026+10.3%
  10. 17 Apr 2026+11.3%

Share of unusual movement by asset

For each asset, the share of CRVS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
soquelitinib
events and moves
973%
Other company news (earnings, financing, releases naming no asset)—6%
Sessions with no dated event—21%

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
ITKSmall molecule
Atopic DermatitisNon-Hodgkin Lymphoma
Peripheral T-Cell Lymphoma
Phase 1/2
adenosine A2ASmall molecule
Multiple MyelomaRenal Cell Carcinoma
MupadolimabNo recent activity
Phase 1
CD73Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
soquelitinibPhase 2Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic
Est. primary completion 2027-06 · NCT07441395 · CT.gov ↗
What to watch
November 2027 (1)
soquelitinibPhase 3Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma …
Est. primary completion 2027-11 · NCT06561048 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 January 2025Topline resultsoquelitinibInterim Phase 1 data from Cohorts 1 and 2 in atopic dermatitis

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$18M$15M+ $188M short-term inv.$20M-$12M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$16M$19M+ $196M short-term inv.$18M-$15M operating cash flowreport ↗
2026-Q1—$11M$237M$14Mreport ↗
2025-Q3—$8.4M$2.9M+ $63M short-term inv.$10M-$9.6M operating cash flowreport ↗
2025-Q2—$7.9M$15M+ $60M short-term inv.$8.0M-$5.8M operating cash flowreport ↗
2025-Q1—$7.5M$5.0M+ $39M short-term inv.—-$8.3M operating cash flowreport ↗
2024-Q3—$5.2M$4.7M+ $37M short-term inv.$40M-$6.3M operating cash flowreport ↗
2024-Q2—$4.1M$15M+ $32M short-term inv.$4.3M-$5.5M operating cash flowreport ↗
2024-Q1—$4.1M$7.5M+ $15M short-term inv.$5.7M-$5.2M operating cash flowreport ↗
2023-Q3—$4.0M$20M+ $12M short-term inv.$6.0M-$5.4M operating cash flowreport ↗
2023-Q2—$4.0M$7.7M+ $29M short-term inv.$6.5M-$5.2M operating cash flowreport ↗
2023-Q1—$4.6M$9.7M+ $25M short-term inv.$7.9M-$8.1M operating cash flowreport ↗
2022-Q3—$10M$25M+ $25M short-term inv.$15M-$6.9M operating cash flowreport ↗
2022-Q2—$4.9M$28M+ $28M short-term inv.$8.4M-$6.1M operating cash flowreport ↗
2022-Q1—$5.1M$31M+ $31M short-term inv.$8.3M-$6.4M operating cash flowreport ↗
2021-Q3—$7.0M$72M+ $4.0M short-term inv.$11M-$8.4M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$34M$4.6M+ $52M short-term inv.$3.8M-$33M operating cash flowreport ↗

Corvus Pharmaceuticals reported no disclosed revenue for fiscal year 2025. R&D spend was $33.72M, up 73.9% YoY, with cash and equivalents of $4.58M at period end. The company recorded a net loss of $15.28M, corresponding to a quarterly net burn of $15.28M.

The company is advancing soquelitinib, its lead ITK inhibitor, in a registrational Phase 3 trial for relapsed peripheral T cell lymphoma and initiated a Phase 2 atopic dermatitis trial in March 2026, following positive cohort 4 results from the earlier atopic dermatitis study announced in January 2026. Ciforadenant continues in an open-label Phase 1b/2 trial for renal cell carcinoma in collaboration with the Kidney Cancer Research Consortium, and next-generation ITK inhibitor candidates remain in preclinical development. A follow-on public offering was completed in January 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$19M$8.7M+ $43M short-term inv.$16M-$25M operating cash flowreport ↗
2023-FY—$17M$13M+ $14M short-term inv.$6.8M-$24M operating cash flowreport ↗
2022-FY—$24M$13M+ $29M short-term inv.$10M-$27M operating cash flowreport ↗
2021-FY—$29M$63M+ $6.0M short-term inv.$11M-$37M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 7 purchases ($384K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Arcara Jeffrey · Chief Business OfficerOpen-market purchase503$10.37$5KForm 4
2026-11-13Arcara Jeffrey · Chief Business OfficerOpen-market purchase500$10.71$5KForm 4
2026-11-12Arcara Jeffrey · Chief Business OfficerOpen-market purchase497$11.12$6KForm 4
2026-11-11Arcara Jeffrey · Chief Business OfficerOpen-market purchase3,000$11.46$34KForm 4
2026-06-11van den Broek Richard · directorAward / grant (derivative)15,000——Form 4
2026-06-11Thompson Peter A. · director, 10% ownerAward / grant (derivative)15,000——Form 4
2026-06-11Grais Linda · directorAward / grant (derivative)15,000——Form 4
2026-06-11CLARK IAN T · directorAward / grant (derivative)15,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 164 reporting institutions held 70.1M shares ($979.7M, 83.1% of shares outstanding).

#InstitutionSharesValue
1ORBIMED ADVISORS LLC7,165,006$104.8M
2BlackRock, Inc.6,160,422$90.1M
3STATE STREET CORP3,565,992$52.2M
4ADAMS STREET PARTNERS LLC3,275,616$47.9M
5VANGUARD CAPITAL MANAGEMENT LLC3,234,538$47.3M
6Vivo Capital, LLC2,805,816$41.0M
7MORGAN STANLEY2,498,825$36.6M
8Deep Track Capital, LP2,491,539$36.5M
9WELLINGTON MANAGEMENT GROUP LLP2,318,517$33.9M
10PERCEPTIVE ADVISORS LLC2,292,441$33.5M
11Commodore Capital LP2,258,735$33.0M
12Foresite Capital Management VI LLC1,831,233$26.8M
13BRAIDWELL LP1,752,798$25.6M
14GEODE CAPITAL MANAGEMENT, LLC1,712,741$25.1M
15MPM BIOIMPACT LLC1,674,875$24.5M